2 terminated, 1 completed, 1 recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Gulam Manji: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat - Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Gulam Manji | 60 | 2024-05-10 | 2026-02-27 |
| Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma Atezolizumab, PEGPH20 - Pancreatic Ductal Adenocarcinoma | Phase 2 | Terminated | Gulam Manji | 1 | 2019-11-01 | 2020-12-23 |
| Perioperative Chemo and Pembrolizumab in Gastric Cancer Pembrolizumab, Standard of care chemotherapy regimen - Gastric Cancer, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Completed | Gulam Manji | 49 | 2017-11-25 | 2024-02-15 |
| PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors PLX3397, sirolimus - Sarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 1 / Phase 2 | Terminated | Gulam Manji | 39 | 2015-11-04 | 2025-03-21 |
Adenocarcinoma (1) · Neurofibrosarcoma (1) · Sarcoma (1) · Stomach Neoplasms (1)
PEGPH20 (1) · Radiosurgery (1) · Sirolimus (1) · atezolizumab (1) · pembrolizumab (1) · pexidartinib (1) · quemliclustat (1) · zimberelimab (1)
United States (4)